Pharmacologic Treatment of Oscillopsia from Nystagmus

depends on the type of nystagmus**, since drug efficacy differs substantially between acquired pendular nystagmus, jerk/gaze-evoked forms, downbeat/upbeat nystagmus, and periodic alternating nystagmus. Overall the evidence base is limited (small crossover RCTs and case series, mostly very low-certainty), and treatment is symptomatic—aimed at reducing slow-phase eye velocity to improve visual acuity and abolish illusory motion.[1][2]

often from multiple sclerosis or oculopalatal tremor:

• Gabapentin (typically up to ~2400 mg/day; trial doses 300 mg four times daily)
• memantine (up to 40–60 mg/day)
  • In a 47-patient placebo-controlled trial gabapetin and memantine were superior to placebo and improved visual acuity, and a double-masked crossover trial found both effective at reducing eye speed and improving acuity, with individual patients responding better to one or the other.[3][2]
  • Gabapentin is generally preferred first-line on tolerability grounds—memantine caused more discontinuations (18.8% vs 6.7%) and can exacerbate MS symptoms, whereas gabapentin was better tolerated.[4][2]
• Topiramate (e.g., 50 mg twice daily) has produced dramatic improvement in refractory APN in a case report when gabapentin/memantine were only partially effective.[5]
• Anticholinergics (trihexyphenidyl, transdermal scopolamine) are largely ineffective and not recommended; results have been inconsistent.[3][2]

• Aminopyridines are the established treatment.
  • 4-aminopyridine (potassium channel blocker)
  • 3,4-diaminopyridine
  • Reduce slow-phase velocity and oscillopsia (two RCTs support use), with 4-AP possibly more potent;
  • the main side effect is transient perioral/distal paresthesia.[1][6]

• memantine.[2]- jerk nystagmus responds less well overall

baclofen (up to ~30 mg/day) is the agent of choice.[7]

A key caveat: no agent reliably abolishes nystagmus, effect sizes are modest, and most data come from very small studies—so treatment is often individualized with trial-and-error and monitoring for ataxia, fatigue, and dizziness.[1][2]

Would you like to explore practical dosing and titration schedules for gabapentin and memantine in acquired pendular nystagmus?

### References

1. Interventions for Eye Movement Disorders Due to Acquired Brain Injury. Rowe FJ, Hanna K, Evans JR, et al. The Cochrane Database of Systematic Reviews. 2018;3:CD011290. doi:10.1002/14651858.CD011290.pub2. 2. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Thurtell MJ, Joshi AC, Leone AC, et al. Annals of Neurology. 2010;67(5):676-80. doi:10.1002/ana.21991. 3. Nystagmus and oscillopsia. Straube A, Bronstein A, Straumann D, European Federation of Neurologic Societies. European Journal of Neurology. 2012;19(1):6-14. doi:10.1111/j.1468-1331.2011.03503.x. 4. Gabapentin and Memantine for Treatment of Acquired Pendular Nystagmus: Effects on Visual Outcomes. Nerrant E, Abouaf L, Pollet-Villard F, et al. Journal of Neuro-Ophthalmology : The Official Journal of the North American Neuro-Ophthalmology Society. 2020;40(2):198-206. doi:10.1097/WNO.0000000000000807. 5. Teaching Video NeuroImage: Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis. Murphy OC, Calabresi PA, Gold DR. Neurology. 2023;100(1):47-48. doi:10.1212/WNL.0000000000201452. 6. Pharmacotherapy of Vestibular and Cerebellar Disorders and Downbeat Nystagmus: Translational and Back-Translational Research. Strupp M, Zwergal A, Feil K, Bremova T, Brandt T. Annals of the New York Academy of Sciences. 2015;1343:27-36. doi:10.1111/nyas.12774. 7. Pharmacotherapy of Vestibular Disorders and Nystagmus. Strupp M, Kremmyda O, Brandt T. Seminars in Neurology. 2013;33(3):286-96. doi:10.1055/s-0033-1354594.